Hepatitis B reactivation in patients receiving targeted therapies.
CONCLUSION: HBV reactivation may occur in patients receiving monoclonal antibodies and TKIs, even with resolved HBV infection status. Although the exact mechanism of TKI-induced HBV reactivation remains unclear, off-target immunological effects of TKI may play an important role in contributing to HBV reactivation.
PMID: 28485688 [PubMed - as supplied by publisher]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
More News: Allergy & Immunology | Antiviral Therapy | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Hepatitis | Hepatitis B | Study